Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 4 Die after Taking SGLT-2 Inhibitors, Causality under Scrutiny
October 15, 2014
- Japan Faces Rocky Road to Ratify Nagoya Protocol on Biodiversity
October 15, 2014
- MHLW Panel OKs Tweaked Requirements for New Development Request Scheme
October 15, 2014
- Council OKs Public-Knowledge Based Application for Solu-Cortef as a Treatment for Bronchial Asthma
October 15, 2014
- Govt Panel Says New Mixed-Care Scheme Is “Patient-Initiated” but Current System Isn’t
October 14, 2014
- National Healthcare Expenditure Hits Record 39 Trillion Yen in FY2012
October 14, 2014
- PFSB Issues Notification on Reporting of Malfunctions of Regenerative Medicine Products
October 14, 2014
- PFSB Issues Notification on Package Inserts of Regenerative Medicine Products
October 14, 2014
- PFSB Announces New Format for ADR Reporting to Be Used Starting in FY2016
October 14, 2014
- MOF Panel to Pitch Reference Pricing for Long-Listed Drugs, Price Cut in FY2015
October 9, 2014
- PMDA Begins Accepting Applications for Regulatory Review Schedule Meetings
October 9, 2014
- Chuikyo to Discuss Handling of Regenerative Medicine Products Under Health Insurance Programs
October 9, 2014
- MHLW to Add Page to Website in FY2016 to Help Hospitals, Pharmacies Select Generic Drug Makers
October 8, 2014
- Minister Calls on Hospitals, Pharmacies to Report Price Settlement Rates within October
October 8, 2014
- Editor’s Pick: Five Healthcare News Headlines for Sept. 22 - Oct. 3
October 6, 2014
- MEXT Redefines Objective of Generic Promotion Subsidy Project to Continue Funding in FY2015
October 6, 2014
- MHLW Panel Agrees that Legal Regulation of Clinical Research Would Be “Difficult”
October 3, 2014
- Govt Panel Calls for Fact-Finding Study for Annual NHI Price Revision
October 3, 2014
- MHLW Issues Guidelines on Package Insert Updates Mandated under Revised PAL
October 2, 2014
- MHLW Issues Warning on ARB, ACE Inhibitors in Pregnant Women
October 1, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…